Cell Membranes As Barriers for The Use of Antisense Therapeutic Agents

Ilpo      Jaaskelainen; Arto      Urtti

Abstract

Antisense oligonucleotides are promising therapeutical agents for numerous diseases resulting from overexpression of genes, expression of mutant genes and viral infections. As most oligonucleotides are polyanions they can not readily pass cellular membranes in adequate amounts to show activity. Therefore, different types of carrier systems and modifications have been developed to enhance absorption and distribution at the level of tissues and cells. The current state of delivery systems will be reviewed with a major part devoted to the commonly used cationic lipids.

Keywords: antisense oligo, antisense molecule, oligonucleotide

« Previous Next »

Rights & Permissions Print Cite

Mini-Reviews in Medicinal Chemistry

Title: Cell Membranes As Barriers for The Use of Antisense Therapeutic Agents

Volume: 2 Issue: 4

Author(s): Ilpo Jaaskelainen and Arto Urtti

Affiliation:

Keywords: antisense oligo, antisense molecule, oligonucleotide

Abstract: Antisense oligonucleotides are promising therapeutical agents for numerous diseases resulting from overexpression of genes, expression of mutant genes and viral infections. As most oligonucleotides are polyanions they can not readily pass cellular membranes in adequate amounts to show activity. Therefore, different types of carrier systems and modifications have been developed to enhance absorption and distribution at the level of tissues and cells. The current state of delivery systems will be reviewed with a major part devoted to the commonly used cationic lipids.

Export Options

Export File:

RIS (for EndNote, Reference Manager, ProCite)

BibTeX

Text

Content:

Citation Only

Citation and Abstract

About this article

Cite this article as:

Jaaskelainen Ilpo and Urtti Arto, Cell Membranes As Barriers for The Use of Antisense Therapeutic Agents, Mini-Reviews in Medicinal Chemistry 2002; 2 (4) . https://dx.doi.org/10.2174/1389557023405891

DOI https://dx.doi.org/10.2174/1389557023405891	Print ISSN 1389-5575
Publisher Name Bentham Science Publisher	Online ISSN 1875-5607

About this journal

Call for Papers in Thematic Issues

Submission closes on : 31 August, 2024

Bioprospecting of Natural Products as Sources of New Multitarget Therapies

According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more

Guest Editor(s): Dr. Marcello Iriti

Submission closes on : 04 June, 2024

Computational Frontiers in Medicinal Chemistry

The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more

Guest Editor(s): Dr. Shaban Ahmad

Submission closes on : 29 September, 2024

Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders

Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more

Guest Editor(s): Dr. Rajeev K. Singla

Submission closes on : 18 September, 2024

Natural Products in Drug Discovery

Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more

Guest Editor(s): Dr. Yu Zhang